The Longevist - Overlay Longevity Research Journal
Area
Publishing
Status
Operational - two editions published
Background
The rise of preprints has accelerated the time taken for discoveries to be shared with the world. However, the sheer volume of new research being published makes it impossible to read everything and thus difficult to have an appreciation of what is the most cutting edge research.
The Longevist solves this problem by curating the most impactful longevity research each quarter!
Each quarter, a shortlist of preprints (sourced from preprint servers such as BioRxiv, MedRxiv, and Arxiv) will be selected by the VitaDAO community and then voted on by our Longevist Curators - a mix of industry & academic experts in the longevity space, consisting of new group leaders to leading professors, communicators, and founders.
The Longevist aims to select 10–20 articles a year - having such a small number should ensure that The Longevist focuses on truly impactful research.
All the shortlisted preprints are available to review on our peer-review platform The Decentralized Longevity Review in return for $VITA.
Articles will be stored on blockchain for permanence & provenance, ensuring robust information storage. Infrastructure will be provided by Snapshot & DeSciLabs
Aims, Hypothesis & Results
Our goal is to promote truly impactful research, with a view to making The Longevist as good as the existing top journals at selecting the top longevity science. The Longevist aims to curate the best - this means success of each selected Longevist article should outperform the journal average in which it is eventually published. Like most websites and journals, we will track success in terms of page views, downloads, citations, tweets, etc.
Once established, we will allow researchers to submit articles, for a fee, for consideration in The Longevist. Acceptance will be determined by an on-chain vote from The Longevist Curators.
The Longevist will help raise awareness and reputational value for VitaDAO, whilst supporting the longevity field, as publishing is the core mechanism by which science is funded, and communicated.
Timeline
The Longevist curates papers from the field of longevity research and is on track to release its first edition of curated papers from Q1 of 2023. The organization plans to continue releasing curated papers on a quarterly basis indefinitely.
Yearly Curation
Required Funding: Maximum 50,000 $USDC and 125,000 $VITA
Duration: Ongoing
Latest Project Updates
Introducing The Longevist - an overlay journal curating the most impactful longevity research every quarter.
We'll showcase top articles from preprint servers like BioRxiv, MedRxiv, and Arxiv.
Discover more projects & initiatives
The Longevity Prize
The Longevity Prize is a series of prizes to award and accelerate progress in longevity and rejuvenation research. It was initiated by VitaDAO and funded through donations through our gitcoin quadratic donation round and partnered with Foresight Institute, Methuselah Foundation and Lifespan.
The VitaDAO Longevity Fellowship
The VitaDAO Longevity Fellowship is aimed at distributing need-based micro grants to help students and early career stage individuals with interest in longevity get more deeply involved in longevity. This is aimed at activities ranging from short term research to attending a conference, or joining a program such as the Longevity Biotech Fellowship.
Humanity - Proprietary Aging Score App
Humanity is a quantified-self app that connects wearables and activity apps to monitor digital biomarkers. The app generates a proprietary aging score, helping users understand activities that slow down or reverse their aging rate. The company uses behavior modification tools and develops biomarkers to guide users toward better healthspan interventions.
Matrix Bio - Long-lived Species Inspired Longevity Biotech
VitaDAO and the Gorbunova Lab are launching Matrix Bio, a cutting-edge research venture leveraging the anti-cancer and pro-longevity effects of high molecular weight hyaluronic acid from naked mole rats to humans.
